论文部分内容阅读
目的 :通过检测治疗前后的前列腺癌 (PC)病人外周血前列腺特异膜抗原信使核糖核酸 (PSMAmRNA)的表达 ,了解原发性前列腺癌的血行播散情况及为前列腺癌综合治疗提供依据。 方法 :采用巢式逆转录—聚合酶链反应 (RT PCR)检测技术 ,对 31例PC病人外周血PSMAmRNA的表达进行了研究。 结果 :31例样本中 ,17例PC病人 (5 4.8% )PSMAmRNA阳性 ,10例正常人和 2 1例良性前列腺肥大 (BPH)病人全阴性 ;10例伴远处转移的PC病人外周血PSMAmRNA全阳性 ,2 1例检测时尚无转移证据者 33.3% (7/ 2 1)阳性 ;外周血PSMAmRNA阳性率与血清PSA水平密切相关 ;根治术或姑息性治疗前、后外周血PSMAmRNA阳性率差异无显著性。 结论 :外周血PSMAmRNA检测可诊断前列腺癌血行播散及转移 ,可作为预测前列腺癌复发、转移的参考指标 ,对外周血PSMAmRNA阳性病人应在围手术期辅以激素、放疗或免疫等辅助治疗 ,以预防肿瘤复发、转移。
Objective: To detect the blood smear of primary prostate cancer (NPC) by detecting the expression of prostate specific membrane antigen messenger RNA (PSMA mRNA) in prostate cancer (PC) patients before and after treatment and to provide basis for the comprehensive treatment of prostate cancer. Methods: The expression of PSMAmRNA in peripheral blood of 31 patients with PC was studied by nested reverse transcription - polymerase chain reaction (RT PCR). RESULTS: PSMA mRNA was positive in 17 cases of PC (5 4.8%), negative in 10 cases of normal and benign prostatic hypertrophy (BPH) in 31 cases. PSMA mRNA in 10 PC patients with distant metastasis was all (33.3%, 7/21) were positive in the detection of no evidence of metastasis. The positive rate of PSMA mRNA in peripheral blood was closely related to the level of serum PSA. There was no significant difference in the positive rate of PSMA mRNA in peripheral blood before and after radical operation or palliative treatment Sex. Conclusion: Peripheral blood PSMA mRNA can be used to diagnose the hematogenous dissemination and metastasis of prostate cancer, which can be used as a reference index to predict the recurrence and metastasis of prostate cancer. PSMA mRNA positive peripheral blood should be supplemented with adjuvant therapy such as hormone, radiotherapy or immune during perioperative period, To prevent tumor recurrence and metastasis.